Pediatric diabetes medications

Hyperglycemia in children with type 1 diabetes after eating pizza can be reduced by fermenting the dough for longer, Italian research shows.

Young people who deliberately omit insulin to either lose weight or prevent weight gain report worse psychosocial functioning, particularly depressive symptoms, than those who have never skipped a dose for this reason, study data show.

Intensive antidiabetic treatment in adults with newly diagnosed type 2 diabetes slows the decline in beta-cell function, but this is not sustained after the treatment is stopped, show the results of the RISE adult medication study.

Children with type 1 diabetes who are aged 6 years or younger have significantly more variability in their insulin needs than adolescents or adults, shows an analysis of closed-loop data.

Factors associated with poor glycemic control in children with type 1 diabetes generally vary according to the insulin regimen used, but family conflict over diabetes management universally impacts all insulin users, US researchers report.

The Ellipse investigators report improved glycemic control at the price of early and mostly mild gastrointestinal events in children and adolescents with type 2 diabetes.

Home use of day and night hybrid closed-loop insulin delivery using the Cambridge model predictive control algorithm is feasible in children aged 1–7 years with type 1 diabetes, researchers report.

The DREAM5 randomized trial has confirmed the efficacy of closed-loop insulin delivery with the MD-logic algorithm in adolescents and young adults without remote monitoring.

Insulin manipulation, the practice of deliberately under- or overdosing insulin, is strongly associated with psychiatric comorbidity in children and young adults with type 1 diabetes, Austrian research shows.

The RISE investigators have reported a continued lack of effect of early intensive therapy on beta-cell function decline in children with prediabetes or early type 2 diabetes.

A randomized trial demonstrates the efficacy of closed-loop insulin delivery in a wide range of patients with poorly controlled type 1 diabetes.

The fixed soluble co-formulation of insulin degludec/insulin aspart offers similar glycemic control to insulin detemir when each are combined with mealtime insulin aspart in children with type 1 diabetes, research shows.

The RISE trial investigators have found that increased insulin resistance and hyperresponsive beta cells may explain the rapid progression of type 2 diabetes in children.

Sulfonylurea treatment is durably effective with a low rate of side effects in patients with permanent neonatal diabetes caused by mutations in the KCNJ11 gene, a study in The Lancet Diabetes & Endocrinology shows.

The majority of adolescents and young adults with type 2 diabetes are still being treated with metformin and/or insulin, despite a growing number of medications being available for adults, US study data show.

Surgical treatment of severely obese adolescents with type 2 diabetes is associated with better glycemic control and a greater reduction in BMI than medical management, US researchers report.

Tubeless insulin pump use can provide long-term improvements in glycemic control at a lower total daily dose of insulin compared with multiple daily injections, show results of a retrospective study among children and young adults with type 1 diabetes.

Research shows that intervening to improve the diet quality of adolescents with type 1 diabetes does not exacerbate disordered eating behavior.

The risk of having a repeat episode of severe hypoglycemia is elevated for at least 4 years after a previous episode in children with type 1 diabetes, although the risk is highest during the first year, researchers report.

Results of AdDIT show that treatment with an ACE inhibitor, a statin, or both does not protect against the increased albumin excretion that frequently occurs in patients with type 1 diabetes during adolescence.